GEN Exclusives

More »

GEN News Highlights

More »
Jan 21, 2009

Athera Signs On Richter-Helm to Produce Cardiovascular Protein Therapeutic

  • Richter-Helm BioLogics will help Athera Biotechnologies with development and manufacturing of its cardiovascular product. The recombinant protein Annexin A5 is intended for the treatment of patients with acute coronary syndrome who are at risk for myocardial infarction.

    “We have now secured cost-competitive and high-quality production for clinical and commercial use,” notes Carina Schmidt, CEO of Athera Biotechnologies.

    Athera’s candidate reported works by preventing plaque rupture and athero-thrombosis through binding of the protein, Annexin A5, to endothelium. It was produced using Richter-Helm's E. coli-based expression system.

    This agreement could include future large-volume commercial production of the molecule for Athera. Richter-Helm will initiate strain and process development of the new process, reaching a 1000 L production scale.

    ---

     



Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

New Drugs for Ebola

Do you think that biopharma companies should not have to go through the normal drug approval process in order to get potential life-saving therapies to Ebola patients more quickly?